- Home
- DOYU vs CNTB Comparison
DOYU vs CNTB Comparison
Compare DOYU & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOYU | CNTB |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.8M | 140.4M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DOYU | CNTB |
|---|---|---|
| Price | $4.72 | $1.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $7.00 | ★ $8.67 |
| AVG Volume (30 Days) | 33.1K | ★ 1.6M |
| Earning Date | 05-19-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.18 | $1.06 |
| 52 Week High | $7.80 | $3.82 |
Technical Indicators
Market Signals| Indicator | DOYU | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 58.47 | 32.35 |
| Support Level | $4.71 | N/A |
| Resistance Level | $4.88 | $2.78 |
| Average True Range (ATR) | 0.13 | 0.26 |
| MACD | 0.04 | -0.10 |
| Stochastic Oscillator | 89.72 | 10.65 |
Price Performance
Historical ComparisonAbout DOYU DouYu International Holdings Limited ADS
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company aims to build an integrated game-centric ecosystem of livestreaming, video, voice, graphic content, and other interactive and community features. The company operates the platform both on mobile apps and PC portals, through which users can enjoy immersive and interactive games and entertainment livestreaming, access a wide array of video and graphic content, and participate in community events and discussions.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.